Evolving therapeutic landscape of advanced hepatocellular carcinoma

Llovet, J. M. et al. Hepatocellular carcinoma. Nat. Rev. Dis. Primers 7, 6 (2021).

PubMed  Google Scholar 

Villanueva, A. Hepatocellular carcinoma. N. Engl. J. Med. 380, 1450–1462 (2019).

CAS  PubMed  Google Scholar 

Akinyemiju, T. et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015. JAMA Oncol. 3, 1683–1691 (2017).

PubMed  PubMed Central  Google Scholar 

Reig, M. et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J. Hepatol. 76, 681–693 (2022).

PubMed  Google Scholar 

Park, J. W. et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int. 35, 2155–2166 (2015).

PubMed  PubMed Central  Google Scholar 

Lai, C. L., Wu, P. C., Chan, G. C., Lok, A. S. & Lin, H. J. Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer 62, 479–483 (1988).

CAS  PubMed  Google Scholar 

Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378–390 (2008).

CAS  PubMed  Google Scholar 

Cheng, A. L. et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J. Clin. Oncol. 31, 4067–4075 (2013).

CAS  PubMed  Google Scholar 

Johnson, P. J. et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J. Clin. Oncol. 31, 3517–3524 (2013).

CAS  PubMed  Google Scholar 

Cainap, C. et al. Linifanib versus sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial. J. Clin. Oncol. 33, 172–179 (2015).

CAS  PubMed  Google Scholar 

Bruix, J. et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 389, 56–66 (2017).

CAS  PubMed  Google Scholar 

Kudo, M. et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391, 1163–1173 (2018).

CAS  PubMed  Google Scholar 

Abou-Alfa, G. K. et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N. Engl. J. Med. 379, 54–63 (2018).

CAS  PubMed  PubMed Central  Google Scholar 

Zhu, A. X. et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 20, 282–296 (2019).

CAS  PubMed  Google Scholar 

Finn, R. S. et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N. Engl. J. Med. 382, 1894–1905 (2020).

CAS  PubMed  Google Scholar 

Cheng, A. L. et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10, 25–34 (2009).

CAS  PubMed  Google Scholar 

Cheng, A. L. et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J. Hepatol. 76, 862–873 (2022).

CAS  PubMed  Google Scholar 

Haber, P. K. et al. Molecular markers of response to anti-PD1 therapy in advanced hepatocellular carcinoma. J. Clin. Oncol. 39, 4100–4100 (2021).

Google Scholar 

Gok Yavuz, B. et al. Current landscape and future directions of biomarkers for immunotherapy in hepatocellular carcinoma. J. Hepatocell. Carcinoma 8, 1195–1207 (2021).

PubMed  PubMed Central  Google Scholar 

Zhu, A. X. et al. Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. Nat. Med. 28, 1599–1611 (2022).

CAS  PubMed  Google Scholar 

Llovet, J. M. et al. Trial design and endpoints in hepatocellular carcinoma: AASLD consensus conference. Hepatology 73, 158–191 (2021).

PubMed  Google Scholar 

Gordan, J. D. et al. Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline. J. Clin. Oncol. 38, 4317–4345 (2020).

CAS  PubMed  Google Scholar 

Llovet, J. M. et al. Immunotherapies for hepatocellular carcinoma. Nat. Rev. Clin. Oncol. 19, 151–172 (2022).

CAS  PubMed  Google Scholar 

Finn, R. S. et al. Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC) [abstract]. J. Clin. Oncol. 37 (Suppl. 15), 4004 (2019).

Google Scholar 

Yau, T. et al. Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial. JAMA Oncol. 6, e204564 (2020).

PubMed  PubMed Central  Google Scholar 

Vogel, A. & Martinelli, E. Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO clinical practice guidelines. Ann. Oncol. 32, 801–805 (2021).

CAS  PubMed  Google Scholar 

Cabibbo, G. et al. First-line immune checkpoint inhibitor-based sequential therapies for advanced hepatocellular carcinoma: rationale for future trials. Liver Cancer 11, 75–84 (2022).

CAS  PubMed  Google Scholar 

Aoki, T. et al. Exploratory analysis of lenvatinib therapy in patients with unresectable hepatocellular carcinoma who have failed prior PD-1/PD-L1 checkpoint blockade. Cancers 12, 3048 (2020).

CAS  PubMed Central  Google Scholar 

Kudo, M. Sequential therapy for hepatocellular carcinoma after failure of atezolizumab plus bevacizumab combination therapy. Liver Cancer 10, 85–93 (2021).

PubMed  PubMed Central  Google Scholar 

Kudo, M. et al. Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib. Eur. J. Cancer 167, 1–12 (2022).

CAS  PubMed  Google Scholar 

Finn, R. S. et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. J. Clin. Oncol. 38, 193–202 (2020).

CAS  PubMed  Google Scholar 

Pinter, M., Scheiner, B. & Peck-Radosavljevic, M. Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups. Gut 70, 204–214 (2021).

CAS  PubMed  Google Scholar 

Pfister, D. et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature 592, 450–456 (2021).

CAS  PubMed  PubMed Central  Google Scholar 

Haber, P. K. et al. Evidence-based management of hepatocellular carcinoma: systematic review and meta-analysis of randomized controlled trials (2002–2020). Gastroenterology 161, 879–898 (2021).

CAS  PubMed  Google Scholar 

Kudo, M. Selection of systemic treatment regimen for unresectable hepatocellular carcinoma: does etiology matter? Liver Cancer 11, 283–289 (2022).

PubMed  PubMed Central  Google Scholar 

Kudo, M. et al. Pembrolizumab as second-line therapy for advanced hepatocellular carcinoma: a subgroup analysis of Asian patients in the phase 3 KEYNOTE-240 trial. Liver Cancer 10, 275–284 (2021).

CAS  PubMed  PubMed Central  Google Scholar 

Qin, S. et al. Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): phase 3 KEYNOTE-394 study [abstract]. J. Clin. Oncol. 40 (Suppl. 4), 383 (2022).

Google Scholar 

Liu, G. et al. Case report: complete response of primary massive hepatocellular carcinoma to anti-programmed death ligand-1 antibody following progression on anti-programmed death-1 antibody. Front. Immunol. 12, 712351 (2021).

CAS  PubMed  PubMed Central  Google Scholar 

Sanduzzi Zamparelli, M. et al. Early nivolumab addition to regorafenib in patients with hepatocellular carcinoma progressing under first-line therapy (GOING trial), interim analysis and safety profile [abstract]. J. Clin. Oncol. 40 (Suppl. 4), 428 (2022).

Google Scholar 

Li, X. et al. A phase I dose-escalation, pharmacokinetics and food-effect study of oral donafenib in patients with advanced solid tumours. Cancer Chemother. Pharmacol. 85, 593–604 (2020).

CAS  PubMed  Google Scholar 

Qin, S. et al. Donafenib versus sorafenib in first-line treatment of unresectable or metastatic hepatocellular carcinoma: a randomized, open-label, parallel-controlled phase II–III trial. J. Clin. Oncol. 39, 3002–3011 (2021).

CAS  PubMed  PubMed Central  Google Scholar 

Qin, S. et al. Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Gastroenterol. Hepatol. 6, 559–568 (2021).

PubMed  Google Scholar 

Giordano, S. & Columbano, A. Met as a therapeutic target in HCC: facts and hopes. J. Hepatol. 60, 442–452 (2014).

CAS  PubMed  Google Scholar 

Wang, H. et al. The function of the HGF/c-Met axis in hepatocellular carcinoma. Front. Cell Dev. Biol. 8, 55 (2020).

CAS  PubMed  PubMed Central  Google Scholar 

Goyal, L., Muzumdar, M. D. & Zhu, A. X. Targeting the HGF/c-MET pathway in hepatocellular carcinoma. Clin. Cancer Res. 19, 2310–2318 (2013).

CAS  PubMed  PubMed Central  Google Scholar 

Bouattou

留言 (0)

沒有登入
gif